Product Name
MARVELD2, siRNA
Full Product Name
MARVELD2 siRNA (Human)
Product Synonym Names
TRIC; MARVEL domain-containing protein 2; Tricellulin
Product Gene Name
MARVELD2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q8N4S9
Specificity
MARVELD2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MARVELD2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of MARVELD2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
MARVELD2 sirna
siRNA to inhibit MARVELD2 expression using RNA interference
Applications Tested/Suitable for MARVELD2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for MARVELD2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001033692.2
[Other Products]
NCBI GenBank Nucleotide #
NM_001038603.2
[Other Products]
UniProt Primary Accession #
Q8N4S9
[Other Products]
UniProt Secondary Accession #
Q96NM9; A1BQX0; A1BQX1; A8KA97[Other Products]
UniProt Related Accession #
Q8N4S9[Other Products]
Molecular Weight
62,796 Da
NCBI Official Full Name
MARVEL domain-containing protein 2 isoform 1
NCBI Official Synonym Full Names
MARVEL domain containing 2
NCBI Official Symbol
MARVELD2 [Similar Products]
NCBI Official Synonym Symbols
Tric; DFNB49; MARVD2; MRVLDC2
[Similar Products]
NCBI Protein Information
MARVEL domain-containing protein 2
UniProt Protein Name
MARVEL domain-containing protein 2
UniProt Synonym Protein Names
Tricellulin
Protein Family
MARVEL domain-containing protein
UniProt Gene Name
MARVELD2 [Similar Products]
UniProt Synonym Gene Names
TRIC [Similar Products]
UniProt Entry Name
MALD2_HUMAN
NCBI Summary for MARVELD2
The protein encoded by this gene is a membrane protein found at the tight junctions between epithelial cells. The encoded protein helps establish epithelial barriers such as those in the organ of Corti, where these barriers are required for normal hearing. Defects in this gene are a cause of deafness autosomal recessive type 49 (DFNB49). Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]
UniProt Comments for MARVELD2
MARVELD2: Plays a role in the formation of the epithelial barriers. The separation of the endolymphatic and perilymphatic spaces of the organ of Corti from one another by epithelial barriers is required for normal hearing. Defects in MARVELD2 are the cause of deafness autosomal recessive type 49 (DFNB49). DFNB49 is a form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, multi-pass; Membrane protein, integral
Chromosomal Location of Human Ortholog: 5q13.2
Cellular Component: tight junction; basolateral plasma membrane; apical plasma membrane; cytoplasm; integral to membrane; cytoplasmic vesicle
Molecular Function: protein binding
Biological Process: intercellular junction assembly and maintenance; sensory perception of sound
Disease: Deafness, Autosomal Recessive 49
Research Articles on MARVELD2
1. High tricellulin expression is associated with hepatocellular carcinoma.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
